$CLDX
Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Perilous Reversal" Stock
By
TheStreet Wire
Follow
| 04/07/16 - 10:03 AM EDT
Get TheStreet Quant Ratings' exclusive 5-page report for (CLDX) now.
Trade-Ideas LLC identified Celldex Therapeutics ( CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Celldex Therapeutics as such a stock due to the following factors:
CLDX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $15.2 million.
CLDX has traded 408,746 shares today.
CLDX is down 3.5% today.
CLDX was up 11.6% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in CLDX with the Ticky from Trade-Ideas. See the FREE profile for CLDX NOW at Trade-Ideas
More details on CLDX:
Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. Currently there are 5 analysts that rate Celldex Therapeutics a buy, no analysts rate it a sell, and 5 rate it a hold.
The average volume for Celldex Therapeutics has been 4.3 million shares per day over the past 30 days. Celldex has a market cap of $432.3 million and is part of the health care sector and drugs industry. The stock has a beta of 2.44 and a short float of 27.2% with 7.12 days to cover. Shares are down 68.8% year-to-date as of the close of trading on Wednesday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
TheStreetRatings.com Analysis:
TheStreet Quant Ratings rates Celldex Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and generally disappointing historical performance in the stock itself.
Highlights from the ratings report include:
The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed compared to the Biotechnology industry average, but is greater than that of the S&P 500. The net income has decreased by 2.7% when compared to the same quarter one year ago, dropping from -$31.82 million to -$32.68 million.
CLDX's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 86.44%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, CELLDEX THERAPEUTICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
CELLDEX THERAPEUTICS INC has improved earnings per share by 8.3% in the most recent quarter compared to the same quarter a year ago. Stable earnings per share over the past year indicate the company has managed its earnings and share float. We anticipate this stability to falter in the coming year and, in turn, the company to deliver lower earnings per share than prior full year. During the past fiscal year, CELLDEX THERAPEUTICS INC continued to lose money by earning -$1.31 versus -$1.32 in the prior year. For the next year, the market is expecting a contraction of 4.2% in earnings (-$1.37 versus -$1.31).
Net operating cash flow has increased to -$13.75 million or 38.12% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of 26.63%.
You can view the full Celldex Therapeutics Ratings Report.
Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Perilous Reversal" Stock
By
TheStreet Wire
Follow
| 04/07/16 - 10:03 AM EDT
Get TheStreet Quant Ratings' exclusive 5-page report for (CLDX) now.
Trade-Ideas LLC identified Celldex Therapeutics ( CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Celldex Therapeutics as such a stock due to the following factors:
CLDX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $15.2 million.
CLDX has traded 408,746 shares today.
CLDX is down 3.5% today.
CLDX was up 11.6% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in CLDX with the Ticky from Trade-Ideas. See the FREE profile for CLDX NOW at Trade-Ideas
More details on CLDX:
Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. Currently there are 5 analysts that rate Celldex Therapeutics a buy, no analysts rate it a sell, and 5 rate it a hold.
The average volume for Celldex Therapeutics has been 4.3 million shares per day over the past 30 days. Celldex has a market cap of $432.3 million and is part of the health care sector and drugs industry. The stock has a beta of 2.44 and a short float of 27.2% with 7.12 days to cover. Shares are down 68.8% year-to-date as of the close of trading on Wednesday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
TheStreetRatings.com Analysis:
TheStreet Quant Ratings rates Celldex Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and generally disappointing historical performance in the stock itself.
Highlights from the ratings report include:
The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed compared to the Biotechnology industry average, but is greater than that of the S&P 500. The net income has decreased by 2.7% when compared to the same quarter one year ago, dropping from -$31.82 million to -$32.68 million.
CLDX's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 86.44%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, CELLDEX THERAPEUTICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
CELLDEX THERAPEUTICS INC has improved earnings per share by 8.3% in the most recent quarter compared to the same quarter a year ago. Stable earnings per share over the past year indicate the company has managed its earnings and share float. We anticipate this stability to falter in the coming year and, in turn, the company to deliver lower earnings per share than prior full year. During the past fiscal year, CELLDEX THERAPEUTICS INC continued to lose money by earning -$1.31 versus -$1.32 in the prior year. For the next year, the market is expecting a contraction of 4.2% in earnings (-$1.37 versus -$1.31).
Net operating cash flow has increased to -$13.75 million or 38.12% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of 26.63%.
You can view the full Celldex Therapeutics Ratings Report.
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
